I’m sure you’ve heard already - Internet geriatric Yahoo just bought six-year old Tumblr for $1.1 billion. The deal, likely to complete in the second half of this year, is almost all cash - reportedly almost all the cash Yahoo had in hand at the close of the first quarter.
Peter Houston asks, could acquisition by Yahoo make Tumblr more interesting to Pharma?
I’m sure you’ve heard already - Internet geriatric Yahoo just bought six-year old Tumblr for $1.1 billion. The deal, likely to complete in the second half of this year, is almost all cash - reportedly almost all the cash Yahoo had in hand at the close of the first quarter. Why has Yahoo fallen so heavily for Tumblr? Easy, Yahoo is seen by many in the digital world as stodgy, slow and quite possibly past it. Tumblr is cool, nimble and on the up.
The Tumblr blogging platform, founded in 2007, posts some pretty impressive numbers: 300 million unique visitors a month; 17 billion page views monthly; 120,000 signups a day; 900 posts a second; and 24 billion minutes spent on the site every month. The clincher is Tumblr’s mobile footprint – more than half its visitors use its mobile app, seven times a day on average.
The bottom line is that a Yahoo-Tumblr combination (Yumblr?) is expected to grow Yahoo’s audience by half, giving it more than a billion monthly visitors, with a projected increase in traffic of approximately 20 percent. Yahoo hopes that it can bring its expertise in personalization and search to suck users into its advertising networks.
This could be a problem as the youthful Tumblr user-base, much like its twentysomething founder David Karp, hates internet advertising. As you might expect there has already been a user backlash against the deal, prompting Yahoo CEO to comment, “Don’t worry we won’t screw it up.”
The most likely way for Yahoo not to screw it up is to focus tightly on content marketing or branded content opportunities by bringing its grown-up content management skills to Tumblr’s nascent sponsored content offering. And this is the point where pharma marketers should start paying attention.
Given the demographic distance between the average Pharma CEO and the average Tumblr user, you have probably never used Tumblr. The easy-to-use blogging platform is used mainly by a 13 to 25 age group attracted by its “social looseness”. Real names are not required on Tumblr, only email addresses, allowing users to present multiple personalities. “Tumblr is, in a way, the anti-Facebook-a social network where you do not have to be friends with your mother,” says a recent Economist Explains post.
When you explore Tumblr today, it’s not difficult to understand why you’ll find very few, if any, Pharma company
Tumblrs. The content is quirky to say the least, from blogs devoted to photos of the late Kim Jong Il looking at things, to collections of dopey texts we parents send our children. Oh, and there’s a fair amount of pornography on there too.
Some major brands and corporations are already on the platform, however. Media - Newsweek, The Boston Globe, Elle Magazine, GQ - was relatively quick to pick up on it, seeing a relatively easy way to distribute a regular stream of highly visual content that would be shared by their audience. Fashion brands like J.Crew and Oscar de La Renta are also taking advantage of the “visual not verbose” ethos of the site. IBM’s Smarter Planet Tumblr is excellent. It features more of a mix of text and images, but the real value is the opportunity to distribute links to the broader network of IBM information elsewhere on the web.
What you will find when you take a closer look at Tumblr is a lot of potential patients. And as Pharma marketers get more serious about “customer-centric” and “multi-platform” approaches, maybe the acquisition by Yahoo is as good a time as any to look again at the platform.
Take a look at the diabeticproblems tag on Tumblr. You’ll see the occasional ‘humorous’ picture from people wondering how they’re going to cope with a chocolate fountain, but the vast majority of posts are from young people dealing with the day-to day-issues of living with diabetes. Questions about travelling with diabetes, snack recommendations for low blood sugar, pictures of testing kits and insulin pumps and a lot of motivational humor. Do you think a Pharma Tumblr offering funny, well-crafted advice and genuine support to this group might get some attention?
I’m not suggesting that anyone switch their social media budget to Tumblr today on the strength of Yahoo’s involvement. But it’s worth keeping an eye on what Yahoo does and how the Tumblr audience reponds. If they get the content marketing part of the play right and the user base keeps active, Tumblr might just make it into your social media marketing plan.
Peter Houston is former Group Content Director for Advanstar Pharma Science. He is now an independent media consultant and founder of Flipping Pages.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.